The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
04. June 2026
The prescribing restriction was made because of the only mild to moderate effectiveness, the strong differences in how well the drugs work from patient to patient, and the side effects …
30. May 2026
The AMNOG-Monitor now has a fresh look. After rebuilding the platform from the ground up last year to handle additional data sources such as EU-HTA and arbitration rulings, we've also …
04. May 2026
The new European health technology assessment (EU-HTA) has reached an important milestone: the first joint assessment – led by Ireland's National Centre for Pharmacoeconomics (NCPE) as assessor and IQWiG as …
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
